Obalon Therapeutics series D and loan for $30 million

Posted on 15 January 2015

Obalon Therapeutics announced the completion of a $20 million Series D private equity financing and a $10 million term loan from Square 1 Bank.

Proceeds of the new financing will be used primarily to fund U.S. clinical trials to support the U.S. Food and Drug Administration (FDA) approval of the Obalon balloon, a novel, nonsurgical, fully-reversible device for weight loss.

Searching for more deal information? Current Partnering offers the following options:

CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

A new syndicate of international investors, including Axon Ventures, Bader Sultan & Bros. Co. W.L.L., Mirae Asset Venture Investment, NeoPlux Co., Ltd. and Striker Asia Opportunities Fund, participated in the $20 million Series D financing along with existing investors, Domain Associates, InterWest Partners and Okapi Venture Capital.

For further deal information visit Current Agreements (subscription required)

View: Top pharmaceutical companies

View: Top biotech companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends